Korea S.E.
19:00:00 2024-03-24 EDT
5-day change
1st Jan Change
2,020
KRW
+9.54%
-.--%
-67.58%
NKMAX CO., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
NKMAX CO., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was KRW 12,783.58 million compared to KRW 12,562.12 million a year ago. Basic loss per share from continuing operations was KRW 335 compared to KRW 367 a year ago.
Diluted loss per share from continuing operations was KRW 335 compared to KRW 367 a year ago. Basic loss per share was KRW 335 compared to KRW 367 a year ago.
NKMAX CO., Ltd. cancelled the transaction announced on October 20, 2023
04-16
CI
NKMAX CO., Ltd.(KOSDAQ:A182400) dropped from S&P Global BMI Index
04-15
CI
NKMAX CO., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
04-05
CI
NKMAX CO., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-14
CI
NKMAX CO., Ltd. announced that it expects to receive KRW 13.39999704 billion in funding
23-10-19
CI
NKMAX CO., Ltd. announced that it has received KRW 7.5 billion in funding
23-09-12
CI
NKMAX CO., Ltd. announced that it has received KRW 8.5 billion in funding
23-09-11
CI
NKMAX CO., Ltd. announced that it expects to receive KRW 7.5 billion in funding
23-09-10
CI
NKMAX CO., Ltd. announced that it expects to receive KRW 8.5 billion in funding
23-09-07
CI
NKMAX CO., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-14
CI
NKMAX CO., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-15
CI
NKMAX CO., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
23-03-19
CI
NKMAX CO., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
22-11-14
CI
NKMAX CO., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
22-08-16
CI
NKMAX CO., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
22-05-16
CI
NKMAX CO., Ltd. announced that it has received KRW 36 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Meritz Securities Co., Ltd., Meritz Capital Co., Ltd., Investment Arm
22-04-14
CI
NKMAX CO., Ltd. announced that it expects to receive KRW 36 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Meritz Securities Co., Ltd., Meritz Capital Co., Ltd., Investment Arm
22-04-06
CI
NKMAX CO., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
22-03-21
CI
NKMAX CO., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
21-11-15
CI
NKMAX CO., Ltd. announced that it has received KRW 21.40019775 billion in funding
21-06-24
CI
NKMAX CO., Ltd. announced that it expects to receive KRW 21.40019775 billion in funding
21-06-07
CI
NKMAX CO., Ltd. announced that it has received KRW 29.9999702 billion in funding from a group of investors
20-12-02
CI
NKMAX CO., Ltd. announced that it expects to receive KRW 29.9999702 billion in funding from a group of investors
20-11-25
CI
NKMAX CO., Ltd. announced that it has received KRW 20 billion in funding from SV Investment Corp., Nongshim Capital Co., Ltd., Investment Arm, Industrial Bank of Korea, Investment Arm, Bir Publishing Co., Ltd, NH Investment & Securities Co., Ltd., Shinhan Investment Corp., Investment Arm, and other investors
20-05-26
CI
NKMAX CO., Ltd. announced that it expects to receive KRW 20 billion in funding from SV Investment Corp., Nongshim Capital Co., Ltd., Investment Arm, Industrial Bank of Korea, Investment Arm, Bir Publishing Co., Ltd, NH Investment & Securities Co., Ltd., Shinhan Investment Corp., Investment Arm, and other investors
20-05-24
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
NKMAX Co., Ltd., formerly ATGen, is a Korea-based company principally engaged in the research, development, manufacturing and supply of biological products. The Company is involved in the production and sale of recombinant proteins, monoclonal antibodies, NK cell activity test kits, cell therapy products, and in the provision of other related services. The NK cell activity test kits are provided under the name of NK Vue. The Company distributes its products within domestic market and to overseas markets.
More about the company
1st Jan change
Capi.
-67.58% 128M +8.29% 113B +10.21% 106B +0.41% 22.27B -11.90% 22.22B -5.99% 19.43B -37.36% 17.87B -5.17% 17.24B +7.70% 14.29B +37.65% 12.52B
Bio Therapeutic Drugs
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
NKMAX CO., LTD. 